Lexeo Therapeutics(LXEO) - 2024 Q2 - Quarterly Results

Financial Performance - Lexeo Therapeutics reported cash and cash equivalents of 175.0 million as of June 30, 2024, expected to fund operations into 2027[4] - Research and development (R&D) expenses increased to 16.6 million for Q2 2024, up from $11.2 million in Q2 2023, representing a 48$7.0 million in Q2 2024, compared to $2.7 million in Q2 2023, marking a 159$21.2 million, or $0.64 per share, compared to a net loss of$13.4 million, or $8.30 per share, in Q2 2023[4] Clinical Development - Interim data from the Phase 1/2 studies of LX2006 showed sustained improvements across multiple cardiac biomarkers in Friedreich ataxia cardiomyopathy[2] - LX2006 was well tolerated with no treatment-related serious adverse events reported to date[3] - Lexeo initiated formal engagements with the FDA regarding surrogate endpoints for a registrational study of LX2006, with an update expected by the end of 2024[3] - The company plans to share additional data from LX2006 at a scientific conference in Fall 2024[4] - Interim data readout for LX2020 (HEROIC-PKP2) is expected in the second half of 2024[4] Leadership Changes - Tim Van Hauwermeiren was appointed to the Board of Directors in July 2024, bringing over 20 years of experience in life sciences[3]